Business
INmune Bio, Inc. to Present Preclinical Data at the 2023 AACR Annual Meeting Showing Improved Outcomes in High-Risk Breast Cancer by Targeting MUC4 Expression with INB03
Two presentations show targeting high-risk MUC4 expressing HER2+ and Triple Negative Breast Cancer with INB03 reverses resistance mechanisms to immunotherapy
About this update from Inmune Bio Inc.
[{"type":"text","content":"Two presentations show targeting high-risk MUC4 expressing HER2+ and Triple Negative Breast Cancer with INB03 reverses resistance mechanisms to immunotherapy \"Emerging Targeted Therapies for HER2-Positive Breast Cancer\" has been published in Cancers as part of a special issue on Targeted Therapeutic Options and Future Perspectives for HER2 Positive Breast Cancer Boca Raton, April 11, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, is presenting data on the use of INB03, a dominant-negative TNF inhibitor of soluble TNF (sTNF) in the treatment of high-risk MUC4 expressing HER2+ and triple negative breast cancer. Roxana Schillaci Ph.D. of Instituto de Biología y Medicina Experimental in Buenos Aries, Argentina, will present data at the American Association of Cancer Research Annual Meeting 2023 in Orlando Florida and has published a paper in Cancers as part of the Special Issue: Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer. MUC4, an easily measured glycoprotein on the cell surface of approximately one third of women with HER2+ or TNBC, predicts poor survival and treatment resistant disease with increased metastatic potential. Several resistance mechanisms are active in MUC4-expressing tumors including resistance to trastuzumab-based antibody drug conjugates such as trastuzumab-deruxtecan (Enhertu™). Neutralizing soluble TNF with INB03, a dominant negative inhibitor of sTNF, decreases MUC4 expression, improves function of trastuzumab based immunotherapies, increases anti-tumor macrophage function, increases tumor infiltrating lymphocyte populations, and decreases the metastatic potential of these high-risk tumors. These changes should improve the response to immunotherapy. \"We understand how MUC4 causes resistance to HER2-targeted therapies and have developed a strategy to overcome this resistance,” said Roxana Schillaci Ph.D., lead scientist on the program from the Instituto de Biología y Medicina Experimental in Buenos Aires, Argentina. “We believe reversing expression in MUC4 in TNBC may provide therapeutic benefits. Reversing drug therapy resistance mechanisms by targeting soluble TNF alpha with INB03 may be a more efficient and...